Journal article
Quality of life and survivorship in patients with low-grade ovarian cancer
Gynecologic oncology, Vol.190, pp.96-103
11/2024
DOI: 10.1016/j.ygyno.2024.08.010
PMCID: PMC11560549
PMID: 39173565
Abstract
High-grade (HGOC) and low-grade ovarian carcinoma (LGOC) are distinct malignancies with different biological features, treatment paradigms, and life expectancies. However, differences in quality of life (QOL), sleep, and depressive symptoms have not been examined by grade, and neither have inflammatory profiles associated with these symptoms. We aim to characterize QOL and biomarkers by OC grade.
Participants included patients with HGOC (N = 578) or LGOC (N = 85). Participants completed baseline assessments of psychosocial factors prior to primary surgery or neoadjuvant chemotherapy and contributed saliva for cortisol and blood for interleukin-6 (IL-6) quantification. Samples were collected intraoperatively to quantify tumor cortisol. General linear models were used to examine differences in biological and psychological variables by grade.
At baseline, patients with LGOC reported less depression (p = 0.018) and sleep disturbances (p = 0.014), but no significant difference in depressive mood (p = 0.11) or QOL (p = 0.51) compared to patients with HGOC, adjusting for age and disease stage. There were trends towards lower tumor cortisol levels (p = 0.078) in LGOC compared to HGOC. One-year post-diagnosis, we found a significant improvement in QOL and fatigue, and a decrease in vegetative depression and IL-6 levels irrespective of grade.
We present the first characterization of psychosocial experiences of patients with LGOC. Despite having a better disease prognosis, patients with LGOC were just as likely to have mood disturbances as those with HGOC. There was a trend towards differences in tumor cortisol by grade. Our findings highlight the need to address well-being in patients with both low- and high-grade ovarian malignancies.
•Low-grade ovarian cancer patients report less vegetative depression than high-grade.•Both low- and high-grade patients report sleep disturbances that do not improve over time.•No difference in overall quality of life by grade at baseline or over time.•Trend towards lower tumor cortisol in low- versus high-grade patients.•No systematic differences in IL-6 or cortisol by grade were observed.
Details
- Title: Subtitle
- Quality of life and survivorship in patients with low-grade ovarian cancer
- Creators
- Mackenzie Lemieux - Washington University in St. LouisRachel Telles - University of IowaMichael Goodheart - University of IowaLaila Dahmoush - University of IowaIan Hagemann - Washington University in St. LouisFrank J. Penedo - University of MiamiRenu Nandakumar - Columbia University Irving Medical CenterSteve W. Cole - University of California, Los AngelesAnil K. Sood - The University of Texas MD Anderson Cancer CenterSusan K. Lutgendorf - University of IowaPremal H. Thaker - Washington University in St. Louis
- Resource Type
- Journal article
- Publication Details
- Gynecologic oncology, Vol.190, pp.96-103
- DOI
- 10.1016/j.ygyno.2024.08.010
- PMID
- 39173565
- PMCID
- PMC11560549
- NLM abbreviation
- Gynecol Oncol
- ISSN
- 0090-8258
- eISSN
- 1095-6859
- Publisher
- Elsevier Inc
- Grant note
- NIH: CA 193249, CA 140933
The project was supported in part by NIH grants CA 193249 and CA 140933 (SKL) . AKS is supported by the American Cancer Society Re-search Professor Award and the Frank McGraw Memorial Chair in Can-cer Research. The content is solely the responsibility of the authors and does not represent the official views of the NIH.
- Language
- English
- Date published
- 11/2024
- Academic Unit
- Psychological and Brain Sciences; Pathology; Iowa Neuroscience Institute; Obstetrics and Gynecology; Urology
- Record Identifier
- 9984699050902771
Metrics
6 Record Views